✦ LIBER ✦

Outcomes associated with amphotericin B lipid complex (ABLC) prophylaxis in high-risk liver transplant patients

✍ Scribed by Saliba, Faouzi; Delvart, Valérie; Ichaï, Philippe; Kassis, Najiby; Botterel, Françoise; Mihaila, Liliana; Azoulay, Daniel; Adam, René; Castaing, Denis; Bretagne, StÉphane; Samuel, Didier

Book ID: 111983432
Publisher: Informa plc
Year: 2013
Tongue: English
Weight: 247 KB
Volume: 51
Category: Article
ISSN: 1365-280X
DOI: 10.3109/13693786.2012.701765

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Targeted prophylaxis with amphotericin B

Targeted prophylaxis with amphotericin B lipid complex in liver transplantation

✍ Saket Singhal; Richard W. Ellis; Stephen G. Jones; Sarah J. Miller; Neil C. Fish 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB

1221 Amphotericin B lipid complex (ABLC)

1221 Amphotericin B lipid complex (ABLC) for fungal sepsis in high-risk immunocompromised patients

✍ Mehta, J.; Powles, R.; Singhal, S.; Jameson, B.; Treleaven, J. 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 172 KB

Clinical Outcomes and Risk Factors of He

Clinical Outcomes and Risk Factors of Hepatitis B Virus Recurrence in Patients Who Received Prophylaxis With Entecavir and Hepatitis B Immunoglobulin Following Liver Transplantation

✍ Kim, Y.-K.; Kim, S.H.; Lee, S.D.; Park, S.-J. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 212 KB

Lamivudine therapy in patients undergoin

Lamivudine therapy in patients undergoing liver transplantation for hepatitis b virus precore mutant-associated infection: High resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immu

✍ McCaughan, Geoffrey W. ;Spencer, Jenean ;Koorey, David ;Bowden, Scott ;Bartholom 📂 Article 📅 1999 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 75 KB 👁 1 views

Recurrent hepatitis B virus (HBV) infection remains a major cause of morbidity and mortality after liver transplantation. Recently, antiviral therapy, such as lamivudine, has become available for prophylaxis against HBV reactivation posttransplantation and for the treatment of HBV recurrent disease.